"hard" MCQ (SBA): Nephrology

Instant feedback + full explanation. One question, done properly.

Hardreduces CKD progression/CV events with less hyperkalemia than steroidal MRAs; still requires monitoring. Continuing spironolactone with high K+ is unsafe; eplerenone shares hyperkalemia risk; amiloride is not indicated for outcome improvement."Nephrology"hard"

A 64-year-old on ACEI and diuretic presents with HFrEF and moderate hyperkalemia after adding spironolactone. He has T2D CKD A3. Which alternative MRA reduces hyperkalemia risk while improving outcomes?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.

"hard" MCQ: Nephrology — Answer & Explanation | iatroX